Leishmania Inhibitors Derived from Deep-Sea Coral

Tech ID: 18B140

Competitive Advantages

  • Specific inhibition of Leishmania donovani parasites
  • A natural drug candidate
  • Does not produce toxic side effects

Summary

Our researchers have identified a novel metabolite derived from an Antarctic marine coral that shows promise as a new treatment option for leishmaniasis infections. Antactic marine invertebrates are being investigated for their natual chemical protective mechanisms used against predators. This natural product chemistry is ideal for new drug development efforts. The identified metabolite has exhibited specific inhibition of Leishmania donovani parasites in laboratory settings.

A Leishmaniasis Infection at the Cellular Level

Desired Partnerships

  • License
  • Sponsored Research
  • Co-Development

Technology Transfer
TTOinfo@usf.edu
(813) 974-0994

Patents